« Back to Record
Citation APA

Van Laethem, J.-L., Melichar, B., Cascinu, S., Saramak, P., Michl, P., Van Brummelen, D., Zaniboni, A., Schmiegel, W., Dueland, S., Giurescu, M., Garosi, V. V., Riess, H., Roth, K., Schulz, A., Seidel, H., Rajagopalan, P., Teufel, M., Childs, B. B., Jassem, J., Haas, M., Martens, U. U., Weekes, C., Peeters, M., Ross, P., & Bridgewater, J. (2017). Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 12(1), 97-109. doi:10.1007/s11523-016-0469-y


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/245726

Van Laethem, J.-L., Melichar, B., Cascinu, S., Saramak, P., Michl, P., Van Brummelen, D., Zaniboni, A., Schmiegel, W., Dueland, S., Giurescu, M., Garosi, V. V., Riess, H., Roth, K., Schulz, A., Seidel, H., Rajagopalan, P., Teufel, M., Childs, B. B., Jassem, J., Haas, M., Martens, U. U., Weekes, C., Peeters, M., Ross, P., & Bridgewater, J. (2017). Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 12(1), 97-109. doi:10.1007/s11523-016-0469-y